美国食品和药物管理局关于软组织填充剂并发症数据的分析。
Analysis of U.S. Food and Drug Administration Data on Soft-Tissue Filler Complications.
机构信息
Department of Dermatology, University of California, San Diego School of Medicine, La Jolla, California.
Kaiser Permanente, Anaheim Hills, California.
出版信息
Dermatol Surg. 2020 Jul;46(7):958-961. doi: 10.1097/DSS.0000000000002208.
BACKGROUND
With the rising popularity of dermal fillers, the number of complications associated with fillers has increased.
OBJECTIVE
To identify and review reports of adverse events involving cosmetic injectable soft-tissue fillers from the FDA Manufacturer and User Facility Device Experience (MAUDE) database from June 1993 to August 2014.
MATERIALS AND METHODS
The authors conducted a search of adverse events within the U.S. Food and Drug Administration database that involved injectable dermal fillers for soft-tissue augmentation from June 1993 to August 2014. Search terms included generic and trade names of commercially available soft-tissue fillers.
RESULTS
Three thousand seven hundred eighty-two complications involving dermal fillers were identified in the MAUDE database. Forty-four percent of complications implicated hyaluronic acid fillers, 40% involved poly-L-lactic acid fillers, 15% complications included calcium hydroxylapatite fillers, and <1% complications arose from polymethylmethacrylate fillers. Common adverse events included lumps, infection, allergic reaction, ischemia, and swelling. Rare events included trigger of autoimmune reactions, visual disturbances, and stroke.
CONCLUSION
Although complications with dermal fillers are infrequent in comparison with the growing number of filler procedures being performed in the United States every year, this study underscores the importance of appropriate skill and training when administering dermal fillers. Physicians using injectable dermal fillers should be trained to recognize potential complications and know how to appropriately manage them.
背景
随着真皮填充剂的日益普及,与填充物相关的并发症数量也有所增加。
目的
从 1993 年 6 月至 2014 年 8 月,从美国食品和药物管理局(FDA)制造商和用户设施设备经验(MAUDE)数据库中识别和审查与美容注射用软组织填充物相关的不良事件报告。
材料和方法
作者对美国食品和药物管理局数据库中涉及 1993 年 6 月至 2014 年 8 月用于软组织增强的注射用真皮填充物的不良事件进行了搜索。搜索词包括商业上可获得的软组织填充物的通用名和商品名。
结果
在 MAUDE 数据库中发现了 3782 种与真皮填充物相关的并发症。44%的并发症涉及透明质酸填充物,40%涉及聚 L-乳酸填充物,15%的并发症包括钙羟磷灰石填充物,<1%的并发症来自聚甲基丙烯酸甲酯填充物。常见的不良事件包括肿块、感染、过敏反应、缺血和肿胀。罕见的事件包括触发自身免疫反应、视力障碍和中风。
结论
尽管与每年在美国进行的越来越多的填充物手术相比,真皮填充物的并发症并不常见,但本研究强调了在进行真皮填充物时适当的技能和培训的重要性。使用注射用真皮填充物的医生应接受培训,以识别潜在的并发症,并知道如何妥善处理这些并发症。